Instapath

About:

Instapath provides digital imaging tools for rapid on-site pathology evaluation to repeat biopsy procedures and increase hospital revenue.

Website: http://www.instapathbio.com

Twitter/X: instapathbio

Top Investors: National Science Foundation, Y Combinator, MassChallenge

Description:

Over 7 million Americans need biopsy procedures every year, costing over $8 billion; 20% of procedures fail to render an accurate diagnosis. Over 1 million patients have to go through costly, painful repeat biopsy procedures. Instapath makes digital microscopic imaging devices that improve rapid on-site evaluation (ROSE) of biopsies, reducing the need for repeat procedures and increasing operating room capacity and hospital revenue.

Total Funding Amount:

$3.16M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Houston, Texas, United States

Founded Date:

2017-07-01

Contact Email:

info(AT)instapathbio.com

Founders:

Mei Wang

Number of Employees:

1-10

Last Funding Date:

2021-03-09

IPO Status:

Private

Industries:

© 2025 bioDAO.ai